# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000886163-25-000012
Filing Date
2025-02-28
Accepted
2025-02-28 16:02:16
Documents
112
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | lgnd-20241231.htm iXBRL | 10-K | 2710534
2 | EX-19.1 | exhibit191_insidertradingc.htm | EX-19.1 | 101874
3 | EX-21.1 | lgnd_123124xexhibit211.htm | EX-21.1 | 8625
4 | EX-23.1 | lgnd_123124xexhibit231.htm | EX-23.1 | 6332
5 | EX-31.1 | lgnd_123124xexhibit311.htm | EX-31.1 | 15839
6 | EX-31.2 | lgnd_123124xexhibit312.htm | EX-31.2 | 15829
7 | EX-32.1 | lgnd_123124xexhibit321.htm | EX-32.1 | 13044
13 |  | lgnd-20241231_g1.jpg | GRAPHIC | 39695
14 |  | lgnd-20241231_g2.jpg | GRAPHIC | 166240
15 |  | lgnd-20241231_g3.jpg | GRAPHIC | 101471
16 |  | lgnd-20241231_g4.jpg | GRAPHIC | 384460
| Complete submission text file | 0000886163-25-000012.txt |  | 17059526

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | lgnd-20241231.xsd | EX-101.SCH | 100358
9 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | lgnd-20241231_cal.xml | EX-101.CAL | 171308
10 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | lgnd-20241231_def.xml | EX-101.DEF | 638308
11 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | lgnd-20241231_lab.xml | EX-101.LAB | 1312641
12 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | lgnd-20241231_pre.xml | EX-101.PRE | 940313
115 | EXTRACTED XBRL INSTANCE DOCUMENT | lgnd-20241231_htm.xml | XML | 2327738

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33093 | Film No.: 25689885
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)